Stock events for biote Corp. (BTMD)
Biote Corp.'s stock has declined by 38.68% over the past six months, with the share price at $2.11 as of March 4, 2026. Key events include the Q3 2025 earnings report, which exceeded EPS expectations but missed revenue estimates, leading to a slight share increase. A voluntary product recall due to potential metal contamination is expected to cost $2.3 million. Analysts project an EPS of $0.08 for Q4 2025. Shares have fallen approximately 55% over the past year due to slower top-line momentum, mixed quarterly earnings, and a less favorable market, with the company experiencing slowing core pellet procedure revenue and negative free cash flow in 2025.
Demand Seasonality affecting biote Corp.’s stock price
Explicit information regarding demand seasonality for Biote Corp.'s products and services was not found. However, reports indicate slowing procedure volumes and declining supplement revenue in recent quarters, suggesting that demand may not be consistently growing.
Overview of biote Corp.’s business
Biote Corp. is a healthcare company focused on hormone optimization, operating within the Medicinal Chemicals & Botanical Products industry. Its core business is the "Biote Method," a practice-building platform that provides certified practitioners with the tools to implement personalized hormone optimization programs, primarily bioidentical hormone replacement pellet therapy. The platform includes education, training, certification, practice management software, inventory management, and marketing support. Biote also sells branded dietary supplements and sterile pellet insertion kits. The company was founded in 2012 and is headquartered in Irving, Texas.
BTMD’s Geographic footprint
Biote Corp. primarily generates revenue from the United States, with a network of over 2,500 healthcare providers. The company also has an expanding international presence, and its headquarters are located in Irving, Texas.
BTMD Corporate Image Assessment
Biote Corp.'s brand reputation has been impacted by lawsuits alleging adverse effects from its hormone treatments, including cancer and cardiac problems. Concerns have been raised about the company's instructions to providers regarding patient lab values and the testing of products from compounding facilities. FDA scrutiny regarding the regulation of hormone treatments as drugs and a voluntary product recall due to potential metal contamination have also affected the brand's reputation. Changes in CFOs have also raised questions about corporate stability.
Ownership
Biote Corp. has a diverse ownership structure, with institutional owners holding 42.6% of the company, individual insiders holding 12.5%, hedge funds holding 21.2%, and the general public holding 23.7%. Major institutional owners include 325 Capital Llc, Bandera Partners LLC, and BlackRock, Inc. Gary Steven Donovitz is the largest individual shareholder, owning 49.26% of the company.
